SCHEMBL17153131

SCHEMBL17153131

CC(C)(C)[Si](C)(C)OCc1cccc(Nc2nccc(-c3ccc(Cl)nc3)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.47
BCR P11274 5/20 0.47
PRKCA P17252 2/20 0.47
PRKCD Q05655 1/20 0.47
PIK3CG P48736 5/20 0.46
PIK3CA P42336 4/20 0.46
PIK3CB P42338 3/20 0.46
CAMK2D Q13557 3/20 0.44
JAK2 O60674 3/20 0.43
JAK3 P52333 3/20 0.43
SRC P12931 2/20 0.43
CDK5 Q00535 1/20 0.42
EGFR P00533 1/20 0.42
PRKACA P17612 1/20 0.42
PRKACG P22612 1/20 0.42
PRKACB P22694 1/20 0.42
MAPT P10636 1/20 0.42
CSNK2A1 P68400 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17153269 0.85 EGFR (0.59) ABL1BCRPRKCAPRKCDPIK3CG
SCHEMBL17153140 0.83 PRKCA (0.49) ABL1BCRPRKCAPRKCDPIK3CG
SCHEMBL17155411 0.83 MAPK10 (0.38) EGFRCSNK2A1
SCHEMBL18412555 0.83 EGFR (0.54) ABL1BCRPRKCAPRKCDPIK3CG
SCHEMBL17153041 0.81 CDK19 (0.41) ABL1BCRPRKCAPRKCDPIK3CG
SCHEMBL17152799 0.81 ABL1 (0.55) ABL1BCRPRKCAPRKCDPIK3CG
SCHEMBL17153051 0.80 EGFR (0.47) ABL1BCRPRKCAPRKCDPIK3CG
SCHEMBL18412553 0.78 PRKCA (0.46) ABL1BCRPRKCAPRKCDPIK3CG
SCHEMBL3510842 0.77 ABL1 (0.75) ABL1BCRPRKCAPRKCDPIK3CG
SCHEMBL17153242 0.76 CDK19 (0.39) ABL1BCRPRKCAPRKCDJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 US disclosed
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 US disclosed
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-01-26 US disclosed
WO-2015150555-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES EEF2K, VPS26B, VPS28 ABL1 3037/4885BCR 4756/4885PRKCA 2842/4885
US-10017509-B2 Macrocylic pyrimidine derivatives EEF2K, VPS26B, VPS28 ABL1 3037/4885BCR 4756/4885PRKCA 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.